Automated quantification of MART1-verified Ki-67 indices: useful diagnostic aid in melanocytic lesions.
暂无分享,去创建一个
Patricia Switten Nielsen | Rikke Riber-Hansen | Torben Steiniche | R. Riber‐Hansen | T. Steiniche | P. S. Nielsen | Eva Spaun | E. Spaun
[1] M. Kornstein,et al. The medicolegal aspect of error in pathology: a search of jury verdicts and settlements. , 2009, Archives of pathology & laboratory medicine.
[2] P. Heenan. Histological Diagnosis of Nevi and Melanoma , 2005 .
[3] A. Patereli,et al. Cell cycle and apoptosis regulators in Spitz nevi: comparison with melanomas and common nevi. , 2007, Journal of the American Academy of Dermatology.
[4] Bonnie L. Balzer,et al. Nevic Mitoses: A Review of 1041 Cases , 2013, The American Journal of dermatopathology.
[5] P. G. Lang,et al. Sentinel-Node Biopsy or Nodal Observation in Melanoma , 2007 .
[6] Patricia Switten Nielsen,et al. Immunohistochemical Double Stains Against Ki67/MART1 and HMB45/MITF: Promising Diagnostic Tools in Melanocytic Lesions , 2011, The American Journal of dermatopathology.
[7] L. Akslen,et al. Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma , 2010, BMC Cancer.
[8] T. Brenn,et al. Pitfalls in the evaluation of melanocytic lesions , 2012, Histopathology.
[9] J. Kril,et al. A Zonal Comparison of MIB1-Ki67 Immunoreactivity in Benign and Malignant Melanocytic Lesions , 2000, The American Journal of dermatopathology.
[10] R. Bergman,et al. MIB-1 monoclonal antibody to determine proliferative activity of Ki-67 antigen as an adjunct to the histopathologic differential diagnosis of Spitz nevi. , 2001, Journal of the American Academy of Dermatology.
[11] M. Bracken,et al. Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis. , 2009, Journal of the National Cancer Institute.
[12] H. Shaw,et al. Should Tumor Mitotic Rate and Patient Age, As Well As Tumor Thickness, be Used to Select Melanoma Patients for Sentinel Node Biopsy? , 2004, Annals of Surgical Oncology.
[13] J. Grichnik,et al. Accurate identification of proliferative index in melanocytic neoplasms with Melan‐A/Ki‐67 double stain , 2010, Journal of cutaneous pathology.
[14] R. Gelber,et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009 , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] M. Nasr,et al. Comparison of pHH3, Ki-67, and Survivin Immunoreactivity in Benign and Malignant Melanocytic Lesions , 2008, The American Journal of dermatopathology.
[16] R. Parwaresch,et al. Proliferation marker Ki-S5 as a diagnostic tool in melanocytic lesions. , 1997, Journal of the American Academy of Dermatology.
[17] H. Schmidt,et al. Proliferation indices of phosphohistone H3 and Ki67: strong prognostic markers in a consecutive cohort with stage I/II melanoma , 2013, Modern Pathology.
[18] Patricia Switten Nielsen,et al. Automated quantification of MART1-verified Ki67 indices by digital image analysis in melanocytic lesions. , 2012, Archives of pathology & laboratory medicine.
[19] E. Berg,et al. World Health Organization Classification of Tumours , 2002 .
[20] Jeffrey E Gershenwald,et al. Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] H. Soyer. Ki 67 immunostaining in melanocytic skin tumors. Correlation with histologic parameters. , 1991, Journal of cutaneous pathology.
[22] R. Scolyer,et al. Melanocytic lesions of the face: diagnostic pitfalls. , 2004, Annals of the Academy of Medicine, Singapore.
[23] Jakob Raundahl,et al. Practical considerations of image analysis and quantification of signal transduction IHC staining. , 2011, Methods in molecular biology.
[24] B. Lebe,et al. The Significance of Ki-67 Proliferative Index and Cyclin D1 Expression of Dysplastic Nevi in the Biologic Spectrum of Melanocytic Lesions , 2007, Applied immunohistochemistry & molecular morphology : AIMM.
[25] H. Kutzner,et al. Frequent Mitotic Activity in Banal Melanocytic Nevi Uncovered by Immunohistochemical Analysis , 2010, The American Journal of dermatopathology.
[26] M. Kallioinen,et al. A prognostic index in skin melanoma through the combination of matrix metalloproteinase-2, Ki67, and p53. , 2011, Human pathology.
[27] M. Selim,et al. Spitz nevi and atypical Spitz nevi/tumors: a histologic and immunohistochemical analysis , 2005, Modern Pathology.
[28] D. Ivan,et al. Use of immunohistochemistry in the diagnosis of melanocytic lesions: applications and pitfalls. , 2010, Future oncology.
[29] R. Reed,et al. Ki-67 and p53 Expression in Minimal Deviation Melanomas as Compared with Other Nevomelanocytic Lesions , 2003, Modern Pathology.
[30] Two-graph Receiver Operating Characteristic , 2002 .
[31] P. Leboit. Pathology and genetics of skin tumours , 2006 .
[32] D. Elder,et al. Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] T. Hasegawa. Histological grading and MIB‐1 labeling index of soft‐tissue sarcomas , 2007, Pathology international.